Innoviva
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily co...
Latest News
6 days ago · zacks.com
Is Innoviva (INVA) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
8 days ago · zacks.com
INVA or MRK: Which Is the Better Value Stock Right Now?Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?
12 days ago · zacks.com
Innoviva (INVA) Tops Q3 Earnings EstimatesInnoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.
29 days ago · businesswire.com
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio.
1 month ago · zacks.com
Do Options Traders Know Something About Innoviva Stock We Don't?Investors need to pay close attention to INVA stock based on the movements in the options market lately.
1 month ago · zacks.com
INVA vs. MRK: Which Stock Is the Better Value Option?Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Innoviva (INVA) or Merck (MRK). But which of these two stocks is more attractive to value investors?
1 month ago · zacks.com
Should Value Investors Buy Innoviva (INVA) Stock?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 months ago · seekingalpha.com
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too PessimisticInnoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.
3 months ago · zacks.com
Innoviva (INVA) Q2 Earnings and Revenues Top EstimatesInnoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.
5 months ago · businesswire.com
Nortiva Bio Launches to Develop Long-Acting Oral MedicinesLEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove INVA